Zymogenetics/Celltech Restenosis Phase II Results Expected By Year-End
Executive Summary
Zymogenetics/Celltech's platelet-derived growth factor receptor antibody CDP 860 Phase II results are expected by the end of the year, Zymogenetics' prospectus for an initial public offering indicates.